Padma Lakshmi and Endometriosis: Her Statements, Advocacy, and What Her Story Means for You

What Padma Lakshmi Has Said About Endometriosis

Padma Lakshmi has been one of the most visible public voices on endometriosis for more than 15 years. Her statements are spread across interviews, op-eds, Senate testimony, and social media. This section pulls those primary sources together and labels clearly where inference fills a gap.

Her Own Words: Suffering in Silence

At the founding of the Endometriosis Foundation of America in 2009, Lakshmi said she "suffered in silence for 23 years" before receiving her diagnosis. She has repeated versions of that framing in multiple interviews, including a 2020 conversation with The New York Times in which she described debilitating cramps that began when she was about 13 and were dismissed by doctors as normal menstrual pain.

In a widely shared 2019 Time essay co-written with EFA co-founder Dr. Tamer Seckin, Lakshmi wrote that she spent years believing severe pelvic pain was simply part of being a woman. That normalization, she argued, is the core cultural and clinical failure driving diagnostic delay.

She has also testified before Congress, calling for increased NIH funding for endometriosis research. Endometriosis receives roughly $16 million per year in NIH funding, a figure advocates including Lakshmi describe as disproportionately low given that endometriosis affects an estimated 190 million women and girls globally.

The Diagnostic Delay She Experienced

Lakshmi's personal delay of approximately 23 years is extreme but not statistically isolated. A 2011 survey published in Fertility and Sterility found that the average time from symptom onset to confirmed surgical diagnosis in the United States was 11.7 years. More recent analyses place the figure between 7 and 10 years as awareness has improved, but the gap remains large.

She has said her diagnosis came through laparoscopy, the current gold standard for definitive diagnosis, after years of being offered only reassurance or pain management without investigation.

What She Has Said About Treatment

Lakshmi has spoken in general terms about hormonal suppression and surgery. She has not publicly named specific medications she takes or has taken. Any claim that she uses a particular branded drug would be inference, not fact, and this article will not make that claim.

She has publicly described surgery as part of her history. Excision surgery, in which endometrial lesions are cut out rather than burned, is preferred over ablation by most specialist societies because excision is associated with lower recurrence rates and better pain outcomes.

The Clinical Reality Behind Her Story

Lakshmi's experience is a case study in a well-documented pattern. Understanding the biology helps explain why her story resonates with so many women.

What Endometriosis Actually Is

Endometriosis is a chronic, estrogen-dependent inflammatory condition in which tissue similar to the uterine lining grows outside the uterus, most commonly on the ovaries, fallopian tubes, and the peritoneum. The resulting lesions produce prostaglandins and inflammatory cytokines that cause pain, adhesions, and in some cases organ damage.

The condition is not simply "bad periods." Pain can be cyclical or constant, pelvic or referred, and it frequently affects bowel, bladder, and sexual function. Women with endometriosis report significantly lower quality of life scores across multiple domains compared to age-matched controls.

Why Diagnosis Takes So Long

Several factors compound the delay Lakshmi experienced:

• Menstrual pain is culturally normalized, so women delay seeking care.
• No reliable non-invasive biomarker exists. CA-125 is non-specific. MRI can suggest deep infiltrating disease but misses superficial lesions.
• Definitive diagnosis requires laparoscopy with histological confirmation, a surgical procedure.
• Symptoms overlap with irritable bowel syndrome, interstitial cystitis, and pelvic inflammatory disease, leading to misattribution.

ACOG Practice Bulletin No. 114 on endometriosis states that clinical diagnosis based on history and examination alone is insufficient, yet laparoscopy is not offered to many women until they have failed multiple empirical treatment trials.

The Estrogen Connection: Why Hormonal Status Matters at Every Life Stage

Endometriosis is driven by estrogen. This has direct implications for you depending on where you are in your reproductive life.

Reproductive years (roughly ages 15 to 45). Disease activity tends to be highest. Hormonal suppression with combined oral contraceptives, progestins such as norethindrone acetate or dienogest, or GnRH agonists/antagonists is the first-line medical approach. The GnRH antagonist elagolix (Orilissa) is FDA-approved specifically for endometriosis-associated pain in premenopausal women and reduces estradiol levels in a dose-dependent way.

Trying to conceive. Endometriosis is found in 30 to 50 percent of women with infertility. Medical suppression prevents pregnancy, so the treatment goal shifts to surgery to restore anatomy, followed by timed conception or assisted reproduction. Lakshmi conceived her daughter after her diagnosis; the specific path she took to conception has not been publicly confirmed.

Perimenopause. Estrogen fluctuates and can be erratic in perimenopause. Some women with endometriosis experience a flare of symptoms during this phase before estrogen declines sufficiently to quiet disease activity. Lakshmi, born in 1970, is in this life stage now. She has not made recent public statements specifically about perimenopause and endometriosis, so any claim about her current symptom status would be speculative.

Post-menopause. Disease typically becomes quiescent after natural menopause. Women on systemic menopausal hormone therapy should generally use combined estrogen-progestogen therapy rather than estrogen alone, because unopposed estrogen may reactivate residual endometriotic implants. This is a clinically meaningful difference from management in women without endometriosis, and ACOG and The Menopause Society both address this distinction.

Does Padma Lakshmi Take Endometriosis Medication?

This is one of the most frequently searched questions about her, and the honest answer is: she has not said.

Lakshmi has discussed her diagnosis, her surgery, and the systemic failures that delayed her care. She has not made public statements naming a current medication regimen. Attributing a specific drug to her would be speculation, and WomanRx will not do that.

What she has done is describe a treatment philosophy: she believes in combining medical management with lifestyle approaches, and she has publicly supported both surgical expertise (specifically excision surgery) and access to specialist care. That framework, while not a prescription, is broadly consistent with current evidence-based guidelines from ACOG and the American Society for Reproductive Medicine.

Pregnancy, Lactation, and Contraception: What Women With Endometriosis Need to Know

This section is required for any discussion of endometriosis treatment, because the drugs used to manage the condition have significant implications for pregnancy and feeding.

Hormonal Suppression Therapies

Combined oral contraceptives (COCs). Not safe in pregnancy. If you are trying to conceive, you must stop COCs and allow time for ovulation to resume, typically one to three cycles. No proven teratogenic risk from inadvertent first-trimester exposure, but COCs are not used during pregnancy.

Progestins (norethindrone acetate, dienogest, medroxyprogesterone acetate). Norethindrone acetate is FDA Pregnancy Category X at contraceptive doses in some formulations and should not be used in pregnancy. Dienogest is not approved in the United States and carries similar contraindications. Depot medroxyprogesterone acetate (DMPA/Depo-Provera) can delay return to fertility for 10 months or more after the last injection, a clinically important consideration for women trying to conceive.

GnRH agonists (leuprolide/Lupron). Contraindicated in pregnancy. Leuprolide can cause fetal harm. The FDA label for leuprolide acetate explicitly states that the drug is contraindicated in pregnancy. Reliable contraception is required during use.

GnRH antagonist elagolix (Orilissa). Also contraindicated in pregnancy and may impair contraceptive efficacy of low-dose progestin-only pills. The FDA label requires a negative pregnancy test before starting and recommends non-hormonal or combined hormonal contraception during treatment.

Lactation

Most hormonal suppression therapies are not recommended during breastfeeding. Combined estrogen-containing pills may reduce milk supply. High-dose progestins have limited data in lactation. GnRH agonists and antagonists lack adequate lactation safety data and are generally deferred until weaning. If you need pain management while breastfeeding, discuss NSAIDs (compatible with breastfeeding in standard doses for short durations) with your provider.

Contraception During Treatment

Several endometriosis drugs are themselves teratogenic or carry fetal risk, yet they do not reliably prevent ovulation. This means you need a separate, reliable contraceptive method if pregnancy is not desired. A copper IUD or a barrier method is typically recommended alongside GnRH-based therapies.

Who Endometriosis Treatment Is Right For, and Who Should Pause

If You Are in Your Reproductive Years With No Immediate Pregnancy Plans

Medical suppression is a reasonable first-line approach for pain management. COCs, norethindrone acetate, or dienogest are often tried before moving to GnRH-based therapies, which carry more side effects including bone density loss with extended use. Leuprolide use beyond 6 months requires add-back therapy (low-dose estrogen-progestogen) to protect bone, and elagolix at 200 mg twice daily is limited to 24 months for the same reason.

If You Are Trying to Conceive

Stop hormonal suppression. Seek evaluation with a reproductive endocrinologist. ASRM guidelines recommend surgical treatment of moderate-to-severe endometriosis before IVF in some but not all cases, and the decision depends on ovarian reserve, partner factors, and prior treatment history.

If You Are Perimenopausal

Symptoms may worsen before they improve. Short-term low-dose hormonal options or non-hormonal pain strategies may be appropriate. Discuss the risk-benefit balance of any systemic hormone therapy with a clinician familiar with endometriosis in midlife, because the evidence base here is thin. Women with endometriosis have been historically under-represented in menopause hormone therapy trials, and most guidance in this subgroup is extrapolated from general menopause data rather than directly studied.

If You Are Post-Menopausal

If you need hormone therapy for menopausal symptoms, combined estrogen-progestogen is generally preferred over estrogen-only therapy to avoid stimulating residual implants. The level of evidence for this recommendation is moderate, derived mostly from case reports and expert consensus rather than randomized trials.

The Broader Advocacy Picture: What the EFA Has Achieved

Lakshmi co-founded the Endometriosis Foundation of America with Dr. Tamer Seckin in 2009. The organization has pursued three main goals: raising disease awareness, funding research, and training the next generation of endometriosis specialists.

One concrete output is the Blossom Ball, an annual fundraiser that has directed millions of dollars toward endometriosis research. Another is the EFA's medical conference, which focuses specifically on surgical education for excision techniques, a skill set that remains unevenly distributed across gynecology training programs.

Lakshmi has used her celebrity to get endometriosis in front of audiences that would not typically encounter the condition in mainstream health coverage. A 2019 Time op-ed she co-authored reached an estimated digital readership in the millions. Her Congressional testimony contributed to language in federal legislation directing NIH to develop a strategic plan for endometriosis research.

NIH published a strategic plan for endometriosis research in 2020, a direct outcome of sustained advocacy pressure from organizations including the EFA. The plan identified four priority areas: understanding disease mechanisms, developing non-invasive diagnostics, improving treatments, and addressing health disparities, since Black and Hispanic women are diagnosed later and less often than white women despite similar or higher prevalence.

This last point is worth sitting with. The diagnostic delay Lakshmi describes is real and documented. For women of color, it is often longer. A 2019 analysis in the American Journal of Obstetrics and Gynecology found that Black women with endometriosis were significantly less likely to receive a laparoscopic diagnosis than white women, reflecting a compounding of the general diagnostic gap with racial bias in pain assessment.

What Her Story Actually Means If You Have Pelvic Pain

Lakshmi's value as an advocate lies partly in her willingness to be specific. She does not describe vague "women's issues." She has named dysmenorrhea, dyspareunia, and bowel symptoms. That specificity gives other women a vocabulary and a reference point.

If you have pelvic pain that is being normalized or dismissed, her story is clinically relevant in a concrete way: it illustrates that the dismissal is a known, documented pattern, not a personal failing. The appropriate next step is not accepting reassurance but requesting a referral to a gynecologist with endometriosis expertise, ideally one trained in excision surgery.

The 2022 ACOG Committee Opinion on chronic pelvic pain recommends a structured diagnostic workup including detailed menstrual history, pelvic exam, transvaginal ultrasound, and consideration of diagnostic laparoscopy when conservative measures fail. Waiting years, as Lakshmi did, is not a clinical necessity. It is a system failure, and knowing that is the first step toward demanding better care.